Quoin Pharmaceuticals, Ltd. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
QNRX Nasdaq 2836 quoinpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Quoin Pharmaceuticals, Ltd.

QNRX: With FDA Clearance to Initiate 2nd NS Whole Body Study for QRX003, Clinical Activities Expand Further - May 28th, 2025 7:13 am
Quoin Pharmaceuticals Says US FDA Clears Second Netherton Syndrome Pivotal Study - May 22nd, 2025 6:07 am
Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study - May 22nd, 2025 5:30 am
Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome - May 20th, 2025 5:30 am
Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study - May 14th, 2025 5:30 am
Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2025 Financial Results - May 13th, 2025 6:00 am
Quoin Pharmaceuticals to Announce First Quarter 2025 Financial Results on Tuesday, May 13, 2025 - May 6th, 2025 6:00 am
Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule - Apr 30th, 2025 5:30 am
Quoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaign - Apr 10th, 2025 5:30 am
Quoin Pharmaceuticals Announces Additional Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient - Apr 2nd, 2025 5:30 am
Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases - Mar 25th, 2025 5:30 am
QNRX: With Clinical Activities Expanding, QNRX Expects Cash Runway Into 2Q26 - Mar 17th, 2025 8:10 am
Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results - Mar 13th, 2025 5:30 am
Quoin Pharmaceuticals to Announce Fourth Quarter and Full-Year 2024 Financial Results on Thursday, March 13, 2025 - Mar 6th, 2025 6:00 am
QNRX: More Positive Data Supporting Efficacy of QRX003 for NS; Campaign to Raise Awareness of the Disease - Mar 5th, 2025 8:16 am
Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications - Mar 4th, 2025 5:30 am
Quoin Pharmaceuticals Announces Highly Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study - Feb 27th, 2025 5:30 am
Quoin Pharmaceuticals Launches First Episode of “NETHERTON NOW” Video Series to Raise Awareness for Netherton Syndrome - Feb 25th, 2025 5:30 am
Quoin Pharmaceuticals Launches ‘NETHERTON NOW’ Campaign to Raise Awareness of Netherton Syndrome, a Rare Genetic Disease with No Approved Treatment or Cure - Feb 4th, 2025 5:30 am
Insider Buyers At Quoin Pharmaceuticals Likely Disappointed With 13% Slide - Feb 2nd, 2025 7:49 am